Antiplatelet therapy is a cornerstone of secondary prevention after non-cardioembolic ischemic stroke and TIA, and a critical component of acute stroke management. The pharmacology spans aspirin, clopidogrel, ticagrelor, prasugrel, dipyridamole, and the newer P2Y12 inhibitors, with evolving understanding of dual antiplatelet therapy (DAPT) timing, monogenic clopidogrel resistance, and the role of cilostazol. This page covers the antiplatelet armamentarium, the evidence-based selection algorithms, and the practical considerations in modern stroke prevention.

Platelet Biology Relevant to Pharmacology

  • Platelet activation requires multiple converging pathways: thromboxane A2 (COX-1), ADP (P2Y12), thrombin (PAR receptors), collagen (GPVI), epinephrine, serotonin.
  • Activated platelets aggregate via GP IIb/IIIa fibrinogen bridging.
  • Antiplatelets block different steps in this cascade.

Aspirin

  • Mechanism: irreversibly acetylates COX-1 → blocks thromboxane A2 synthesis → reduces platelet aggregation; effect lasts the lifespan of the platelet (~7-10 days).
  • PK: rapid absorption; hydrolyzed to salicylic acid; renal clearance.
  • Dose: 81 mg or 325 mg daily; low-dose (75-100 mg) provides full COX-1 inhibition.
  • Uses: secondary stroke prevention; acute stroke (within 24-48 hours); primary prevention (high-risk patients with concurrent ASCVD risk).
  • Side effects: GI bleeding (dose-dependent), intracranial hemorrhage (small absolute risk), tinnitus, hypersensitivity.
  • Aspirin resistance: clinically defined; controversial; some COX-1 polymorphisms.

Clopidogrel

  • Mechanism: prodrug; activated by CYP2C19 (primary) and CYP3A4; active metabolite irreversibly binds P2Y12 ADP receptor → inhibits ADP-induced platelet aggregation.
  • PK: half-life of active metabolite ~30 min; effect lasts 7-10 days.
  • Dose: 75 mg daily (or 300-600 mg loading in ACS/PCI).
  • Uses: secondary stroke prevention (alternative to aspirin); DAPT for short-term post-stroke; ACS.
  • CYP2C19 polymorphism:
    • Poor metabolizers (~15% of Asians, 3-5% Whites): reduced active drug, reduced platelet inhibition.
    • FDA black box warning.
    • Genotyping increasingly considered; some institutions test routinely.
    • Alternatives in PMs: ticagrelor, prasugrel.
  • PPI interaction: omeprazole, esomeprazole inhibit CYP2C19 → reduce clopidogrel effect; clinical significance debated; pantoprazole has less effect.

Ticagrelor

  • Mechanism: reversible, direct P2Y12 antagonist (does not require activation); affects all patients regardless of CYP2C19 status.
  • PK: half-life 7-12 hours; twice-daily dosing.
  • Uses: ACS; secondary stroke prevention in CYP2C19 PMs or as alternative to clopidogrel.
  • SOCRATES trial: ticagrelor vs aspirin in acute stroke — non-significantly different.
  • THALES trial: ticagrelor + aspirin DAPT in minor stroke — superior to aspirin alone.
  • Side effects: dyspnea (mechanism unclear; usually transient), bradycardia.

Prasugrel

  • Mechanism: P2Y12 antagonist; more potent than clopidogrel; less dependent on CYP2C19.
  • Uses: ACS with PCI; NOT recommended for primary stroke prevention.
  • Contraindicated: prior stroke or TIA (increased intracranial hemorrhage risk).
  • Caution: age >75, low body weight (<60 kg).

Dipyridamole (and Aspirin-Dipyridamole)

  • Mechanism: inhibits adenosine reuptake and phosphodiesterase → increases cAMP in platelets → reduced activation.
  • Extended-release + aspirin (Aggrenox): ESPRIT, ESPS-2 trials showed benefit over aspirin alone in stroke prevention.
  • Side effects: headache (often dose-limiting), GI; “coronary steal” theoretical concern in CAD.
  • Less commonly used now due to headache.

Cilostazol

  • Mechanism: phosphodiesterase 3 inhibitor; increases cAMP in platelets; vasodilation.
  • Uses: intermittent claudication; secondary stroke prevention (especially in Asia, where it’s commonly used).
  • CSPS.com trial: cilostazol + aspirin or clopidogrel reduced recurrent stroke.
  • Contraindicated: heart failure (CHF) — black box warning.
  • Side effects: headache, GI, palpitations.

GP IIb/IIIa Inhibitors

  • Abciximab, eptifibatide, tirofiban: block fibrinogen binding to GPIIb/IIIa.
  • Used in interventional cardiology; investigational in stroke.
  • Tirofiban: small studies in acute stroke before/with mechanical thrombectomy.
  • Bleeding risk high.

Selection Algorithm for Secondary Stroke Prevention

Non-Cardioembolic Stroke or TIA

  • Aspirin 81-325 mg daily: first-line.
  • Clopidogrel 75 mg daily: alternative or if aspirin-intolerant.
  • Aspirin + extended-release dipyridamole: alternative (often limited by headache).
  • No clear benefit of dual long-term aspirin + clopidogrel for routine stroke prevention (CHANCE excluded long-term DAPT; MATCH trial showed no benefit).

Short-Term Dual Antiplatelet Therapy (DAPT)

For minor stroke (NIHSS ≤3) or high-risk TIA (ABCD² ≥4):

  • CHANCE trial (China): aspirin + clopidogrel for 21 days reduced recurrent stroke at 90 days.
  • POINT trial (US): aspirin + clopidogrel for 90 days reduced recurrent stroke but increased bleeding; optimal duration is 21-30 days.
  • THALES trial: ticagrelor + aspirin for 30 days (alternative).
  • Current guidelines: aspirin + clopidogrel for 21 days followed by monotherapy.
  • Consider for symptomatic intracranial atherosclerosis (longer duration may be needed).

Symptomatic Intracranial Atherosclerosis

  • SAMMPRIS trial: aggressive medical therapy (DAPT for 90 days + statin + risk factor control) superior to stenting.
  • DAPT typically 90 days then monotherapy.

Carotid Stenosis

  • Asymptomatic: aspirin + statin; consider revascularization.
  • Symptomatic high-grade stenosis: aspirin + DAPT around carotid intervention; revascularization (CEA or CAS).

Vertebral Artery Disease

  • Aspirin + clopidogrel; statin.
  • Revascularization rarely.

Antiplatelet in Specific Scenarios

Acute Ischemic Stroke

  • If not receiving tPA: aspirin 162-325 mg within 24-48 hours.
  • If receiving tPA: aspirin delayed to 24 hours after.
  • If receiving thrombectomy: similar timing; coordinate with team.
  • Minor stroke / high-risk TIA: consider DAPT (clopidogrel + aspirin) for 21-30 days.

Bleeding/Hemorrhage Management on Antiplatelets

  • Hold antiplatelet for significant bleeding.
  • Platelet transfusion if life-threatening bleed (especially intracranial); efficacy debated for clopidogrel/ticagrelor.
  • DDAVP may reduce bleeding time.
  • Restart after stabilization; timing case-by-case.

Antiplatelet for Atrial Fibrillation

  • Antiplatelet alone INFERIOR to anticoagulation for stroke prevention in AF.
  • Reserve antiplatelet for AF patients who cannot tolerate or have contraindications to anticoagulation.

Pregnancy

  • Low-dose aspirin (81 mg) safe; sometimes used for preeclampsia prophylaxis.
  • Clopidogrel data limited; generally avoid unless necessary.

Newer/Emerging Antiplatelets

  • Vorapaxar: PAR-1 antagonist (thrombin receptor); secondary prevention of MI/PAD; NOT recommended for stroke (intracranial hemorrhage risk).
  • P-selectin inhibitors: investigational.
  • Factor XI inhibitors: emerging; may offer less bleeding than current anticoagulants.

🔍 Did You Know?

Pharmacogenomic-guided antiplatelet selection is increasingly entering routine clinical practice and represents one of the most promising applications of precision medicine in neurology. The CYP2C19 polymorphism affecting clopidogrel activation is well-established: poor metabolizers (PMs, ~15% of East Asians, 3-5% of Whites and Black populations) have substantially reduced active clopidogrel metabolite levels and demonstrate increased risk of recurrent stroke or MACE in observational and trial data. Several institutions now offer rapid (≤24 hour) CYP2C19 genotyping in the ED for acute stroke patients being started on clopidogrel, allowing tailored selection: PMs receive ticagrelor instead of clopidogrel (ticagrelor does not require CYP activation). The CHANCE-2 trial and other studies have demonstrated benefit for genotype-guided antiplatelet selection in some populations. The lesson generalizes: polymorphisms in drug-activating enzymes can convert an effective drug into an inactive one, and pharmacogenomic testing is increasingly justified when alternatives exist. For practicing stroke neurologists, the question “could this patient be a clopidogrel non-responder?” should be considered in any patient with recurrent stroke on clopidogrel. The same principle applies to other domains: codeine for analgesia (CYP2D6 metabolism), warfarin dosing (CYP2C9 + VKORC1), and many others. Pharmacogenomics is becoming standard of care, not a research tool.

Pitfalls and Pearls

  • Aspirin: COX-1 acetylation; lifelong platelet effect; 81 mg adequate.
  • Clopidogrel: P2Y12 antagonist; CYP2C19 prodrug; PMs reduced response.
  • Ticagrelor: direct P2Y12 antagonist; no CYP dependence; alternative for PMs; dyspnea side effect.
  • Prasugrel: CONTRAINDICATED post-stroke (ICH risk).
  • Aspirin + dipyridamole: limited by headache.
  • Cilostazol: secondary stroke prevention (especially in Asia); contraindicated in CHF.
  • DAPT for minor stroke / high-risk TIA: aspirin + clopidogrel for 21-30 days.
  • SAMMPRIS: aggressive medical therapy for symptomatic intracranial atherosclerosis.
  • Long-term DAPT: no benefit over monotherapy for routine stroke prevention; increases bleeding.
  • Antiplatelet in AF: INFERIOR to anticoagulation; reserve for contraindications.
  • CYP2C19 testing: increasingly used to guide clopidogrel vs ticagrelor.
  • Acute ischemic stroke: aspirin within 24-48 hours; delay to 24h after tPA.
  • Platelet transfusion for clopidogrel bleeding: clinical efficacy debated.
  • PPI + clopidogrel: pantoprazole less interaction than omeprazole.
  • Vorapaxar: PAR-1; do NOT use in stroke patients (ICH risk).

References

  1. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke. 2021;52(7):e364-e467.
  2. Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE). N Engl J Med. 2013;369(1):11-19.
  3. Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA (POINT). N Engl J Med. 2018;379(3):215-225.
  4. Johnston SC, Amarenco P, Denison H, et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA (THALES). N Engl J Med. 2020;383(3):207-217.
  5. Chimowitz MI, Lynn MJ, Derdeyn CP, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis (SAMMPRIS). N Engl J Med. 2011;365(11):993-1003.
  6. Wang Y, Chen W, Lin Y, et al. Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischemic attack (CHANCE-2). BMJ. 2021;373:n1330.